| Company Name: |
Ribobay Gold |
| Tel: |
(86) 0550-5361572 13958538646 |
| Email: |
lvmenglin@ribobay.com |
| Company Name: |
Apextide Co Ltd Gold |
| Tel: |
15300650552; 15300650552 |
| Email: |
info@apextide.com |
| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
ALN-AS1 manufacturers
- Givosiran
-
- $2.00
-
2026-08-25
- CAS:1639325-43-1
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 100kg
|
| | ALN-AS1 Basic information |
| Product Name: | ALN-AS1 | | Synonyms: | ALN-AS1;Givosiran/ALN-AS1;1H-Thieno[3,4-d]imidazole-4-pentanamide, N-[2-[[(3′,6′-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9′-[9H]xanthen]-5-yl)carbonyl]amino]ethyl]hexahydro-2-oxo-, (3aS,4S,6aR)- (ACI);Givosiran | | CAS: | 1639325-43-1 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![ALN-AS1 Structure]() |
| | ALN-AS1 Chemical Properties |
| storage temp. | Store at -20°C | | form | Solid | | color | White to off-white | | Sequence | RNA, (Cm-sp-Am-sp-Gm-Am-Am-Am-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)G-Um-(2'-deoxy-2'-fluoro)C-Um-(2'-deoxy-2'-fluoro)C-Am-Um-Cm-Um-Um-Am), 3'-[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]- 14,14-bis[[3-[[3-[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa13,20,24-triazanonacos-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)A-sp-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)A-Gm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)A-Cm-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Gm-sp-Gm-sp-Um) (1:1) |
| | ALN-AS1 Usage And Synthesis |
| Uses | Givosiran (ALN-AS1) is a small interfering RNA that targets hepatic aminolevulinate synthase 1 (ALAS1) messenger RNA. Givosiran downregulates ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels. Givosiran can be used for the research of acute intermittent porphyria[1][2]. | | References | [1] Scott LJ. Givosiran: First Approval. Drugs. 2020 Feb;80(3):335-339. DOI:10.1007/s40265-020-01269-0
[2] Balwani M, et, al. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. N Engl J Med. 2020 Jun 11;382(24):2289-2301. DOI:10.1056/NEJMoa1913147 |
| | ALN-AS1 Preparation Products And Raw materials |
|